Volume 27, Number 7—July 2021
Research Letter
Anthemosoma garnhami in an HIV-Infected Man from Zimbabwe Living in South Africa
Table
Laboratory test | Dates |
Reference values | ||||
---|---|---|---|---|---|---|
2019 May 31 | 2019 Jun 7* | 2019 Jun 20 | 2020 Aug 31† | 2020 Nov 11 | ||
Hemoglobin, g/L | 45 | 40 | 92 | 59 | 96 | 132–173 |
Mean cell volume, × 1015/L | 82 | 73 | 84 | 81 | 84 | 80–99 |
Leukocyte count, × 109/L | 0.34 | 2.4 | 3.6 | 2.2 | 3.8 | 4–11 |
Platelet count, × 109/L | 123 | 140 | 184 | 56 | 103 | 137–373 |
Reticulocytes, % | 5.6 | 0.5–1.5 | ||||
Creatinine, mg/dL | 0.79 | 0.5–1.5 | ||||
Total bilirubin, mg/dL | 0.41 | 0.3–1.0 | ||||
Aspartate transaminase, U/L | 111 | 10–30 | ||||
Alanine transaminase, U/L | 19 | 47 | 10–40 | |||
Lactate dehydrogenase, U/L | 922 | 100–200 | ||||
Haptoglobin, g/L | <0.1 | 0.3–2.0 | ||||
CD4, cells/mm3 | 70 | 195 | 500–1,200 | |||
HIV ELISA | Positive | |||||
Sputum Xpert MTB/RIF‡ | Negative |
*Date of treatment initiation. †Date of recrudescence and retreatment initiation. ‡Mycobacterium tuberculosis and rifampin resistance testing (Cepheid, https://www.cepheid.com).
Page created: May 04, 2021
Page updated: June 17, 2021
Page reviewed: June 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.